The stock of Collagen Solutions PLC (LON:COS) is a huge mover today! The stock increased 1.11% or GBX 0.07 on November 18, hitting GBX 6.19. About 112,687 shares traded hands or 63.11% up from the average. Collagen Solutions PLC (LON:COS) has declined 2.00% since April 19, 2016 and is downtrending. It has underperformed by 6.43% the S&P500.
The move comes after 7 months positive chart setup for the GBX 11.66M company. It was reported on Nov, 18 by Barchart.com. We have GBX 14.36 PT which if reached, will make LON:COS worth GBX 15.39 million more.
Collagen Solutions PLC (LON:COS) Ratings Coverage
Out of 2 analysts covering Collagen Solutions (LON:COS), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. GBX 18 is the highest target while GBX 10 is the lowest. The GBX 10 average target is 61.55% above today’s (GBX 6.19) stock price. Collagen Solutions has been the topic of 6 analyst reports since September 16, 2015 according to StockzIntelligence Inc. As per Thursday, September 15, the company rating was maintained by Panmure Gordon. The stock of Collagen Solutions PLC (LON:COS) earned “Buy” rating by Panmure Gordon on Monday, July 11. The stock has “Buy” rating given by Panmure Gordon on Wednesday, November 18. The rating was maintained by Beaufort Securities with “Buy” on Tuesday, July 12. The stock of Collagen Solutions PLC (LON:COS) has “Buy” rating given on Thursday, October 13 by Panmure Gordon. Panmure Gordon maintained it with “Buy” rating and GBX 12.50 target price in Wednesday, September 16 report.
More news for Collagen Solutions PLC (LON:COS) were recently published by: Businesswire.com, which released: “Collbio Limited undertakes US acquisition and reverse listing creating …” on January 27, 2014. Businesswire.com‘s article titled: “Collagen Solutions To Acquire Leading NZ Based Providers of Medical Grade …” and published on November 21, 2014 is yet another important article.
Collagen Solutions plc is a holding company. The company has a market cap of 11.66 million GBP. The Firm is engaged in the business of supply, development and manufacture of medical grade collagen components and biomaterials. It currently has negative earnings. The Company’s services and products are utilized in the research, diagnostics, medical devices and regenerative medicine markets.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.